Itch, also called pruritus, affects 15% of the global population, disrupts sleep, and impacts quality of life. Traditional methods of measuring itch rely on subjective surveys, which can be inaccurate and are prone to bias. Alternatively, wearable devices offer a continuous, objective data-driven approach to quantifying itch by measuring scratch, but thus far, their performance has been mixed. Worn on the back of the hand, Sibel’s ADAM™ sensor stands out by using AI to detect scratching with 99% accuracy. In prior validation efforts, the ADAM sensor was shown to accurately identify nighttime scratching in adults and children with atopic dermatitis, matching results from infrared video recordings. The device is being used in clinical trials by major global pharmaceutical companies like Almirall as a novel digital endpoint.

“Digital endpoints enabled by wearable devices like the ADAM sensor represent a paradigm shift in the way a drug’s therapeutic effect is measured,” says Evan Lund, Sibel’s Head of Business Development for clinical trials. “We believe that the ADAM sensor is the best validated digital endpoint for scratch monitoring in clinical trials, and we’re proud that it’s one of only a handful of digital health technologies accepted into the FDA’s Drug Development Tools program.”